

2 **Prediction of different ovarian responses using anti-Müllerian**
3 **hormone following a long agonist treatment protocol for IVF**

4 **Z. Heidar¹ · M. Bakhtiyari^{2,3} · M. Mirzamoradi¹ · S. Zadehmodarres¹ · F. S. Sarfjoo⁴**

5 Received: 14 January 2015 / Accepted: 21 April 2015
6 © Italian Society of Endocrinology (SIE) 2015

7 **Abstract**

8 *Objective* The purpose of this study was to predict the
9 **AQ1** poor and excessive ovarian response using anti-Müllerian
10 hormone (AMH) levels following a long agonist protocol
11 in IVF candidates.

12 *Research design and methods* Through a prospective
13 cohort study, the type of relationship and appropriate scale
14 for AMH were determined using the fractional polynomial
15 regression. To determine the effect of AMH on the
16 outcomes of ovarian stimulation and different ovarian
17 responses, the multi-nominal and negative binomial regres-
18 sion models were fitted using backward stepwise method.
19 The ovarian response of study subject who entered a stand-
20 ard long-term treatment cycle with GnRH agonist was eval-
21 uated using prediction model, separately and in combined
22 models with (ROC) curves.

23 *Results* The use of standard long-term treatments with
24 GnRH agonist led to positive pregnancy test results in

30 % of treated patients. With each unit increase in the log 25
of AMH, the odds ratio of having poor response compared 26
to normal response decreases by 64 % (OR 0.36, 95 % CI 27
0.19–0.68). Also the results of negative binomial regression 28
model indicated that for one unit increase in the log of AMH 29
blood levels, the odds of releasing an oocyte increased 24 % 30
(OR 1.24, 95 % CI 1.14–1.35). The optimal cut-off points of 31
AMH for predicting excessive and poor ovarian responses 32
were 3.4 and 1.2 ng/ml, respectively, with area under curves 33
of 0.69 (0.60–0.77) and 0.76 (0.66–0.86), respectively. 34

Conclusion By considering the age of the patient under-**AQ2** 35
going infertility treatment as a variable affecting ovulation, 36
use of AMH levels showed to be a good test to discriminate 37
between different ovarian responses. 38

Keywords Prediction · AMH · Cut-off value · Ovarian 39
response 40

Introduction 41

Clinical knowledge and technological advances in recent 42
years have greatly contributed to the success of assisted 43
reproductive technologies, particularly IVF. However, the 44
number of oocytes produced by ovaries after hormonal 45
stimulation is still one of the most important factors for 46
success in this field [1]. In other words, one of the major **AQ3** 47
limiting factors in the success of IVF is the poor ovarian 48
response which is observed in 10–15 % of women undergo- 49
ing IVF [2]. Thus, study of ovarian reserve before assisted 50
reproductive treatments is necessary [3]. Ovarian reserve as 51
potential ovarian function reflects the quantity and quality 52
of oocytes in the ovary [4]. 53

Today, with advances in reproductive medicine, a large 54
part of the research is focused on the study of ovarian 55

A1 ✉ M. Bakhtiyari
A2 Mahmood.bakhtiyari@gmail.com
A3 F. S. Sarfjoo
A4 Monasarfjoo@yahoo.com

A5 ¹ Infertility and Reproductive Health Research Center, Shahid
A6 Beheshti University of Medical Sciences, Tehran, Iran

A7 ² Prevention of Metabolic Disorders Research Center,
A8 Research Institute for Endocrine Sciences, Shahid Beheshti
A9 University of Medical Sciences, Tehran, Iran

A10 ³ Department of Epidemiology and Biostatistics, School
A11 of Public Health, Tehran University of Medical Sciences,
A12 Tehran, Iran

A13 ⁴ Department of Obstetrics and Gynecology, Mahdiyeh
A14 Hospital, Infertility and Reproductive Health Research
A15 Center, Shahid Beheshti University of Medical Sciences,
A16 Tehran, Iran



56 reserve. Overall goals of these researches are as follows:
 57 (a) improving the safety of ovarian stimulation techniques
 58 by identifying patients with high responsiveness (who are
 59 at higher risk of OHSS), (b) improving the effectiveness
 60 of ovarian stimulation techniques (through adjustment of
 61 stimulation dose) and (c) the use of ovarian reserve as a
 62 tool for predicting the outcome of IVF. Therefore, we can
 63 say that identification of young women with low ovarian
 64 reserve who are in similar conditions to older premenopausal
 65 women and informing them about this issue as a clinical
 66 need is of great importance [4].

67 Achieving satisfactory results in assisted reproductive
 68 technology requires careful evaluation of the patient and
 69 study of her ovarian reserve [5]. A proper ovarian reserve
 70 test should be able to predict the odds of pregnancy and
 71 birth of live babies in an infertile population that refer for
 72 fertility treatment and determine the optimum dose of the
 73 hormone selected for ovarian stimulation [6].

74 Some studies have introduced ovarian volume meas-
 75 urement and antral follicle count (AFC) as useful tests for
 76 assessment of ovarian reserve [7–10]. Among the other
 77 ovarian reserve tests, determining FSH (follicle-stimulating
 78 hormone) levels, inhibin-B serum levels and AFC can be
 79 mentioned [4].

80 AM is one of the hormones that have recently been
 81 taken into consideration as a marker for predicting ovar-
 82 ian response before application of assisted reproductive
 83 technology [11–13]. This hormone is produced by ovarian
 84 granulosa cells and its level slowly starts to decline after
 85 puberty and disappears at menopause [5]. Inhibition of
 86 initial follicular recruitment, inhibition of FSH-dependent
 87 growth, and selection of preantral and small antral folli-
 88 cles are among the functions of this hormone [14]. Since
 89 anti-Müllerian hormone (AMH) serum levels are cor-
 90 related with the number of early antral follicles, it can be
 91 used to assess the fertility potential and ovarian response
 92 in IVF [5]. Based on a study, the measurement of AMH
 93 level is currently the ideal test to determine ovarian reserve
 94 which is equal to AFC, but better than FSH, estradiol, LH,
 95 and inhibin-B in terms of sensitivity and specificity [15].
 96 FSH, inhibin-B, and estradiol have a low sensitivity in the
 97 early stages of ovarian reserve reduction. These three hor-
 98 mones are part of a feedback system and their serum levels
 99 are not independent of each other. In addition, changes in
 100 serum levels of these three hormones occur relatively late
 101 in reproductive aging process, when the ovarian reserve
 102 has reached the crisis point and chances of pregnancy have
 103 significantly decreased [16]. However, AMH serum level
 104 is independent of menstrual cycle and is not affected by
 105 GnRH agonists or oral contraceptives [17]. Although AMH
 106 is currently known as a reliable and promising marker in
 107 predicting ovarian response before using assisted repro-
 108 ductive technology, the cut-off level of this hormone to

determine the minimum and maximum ovarian response
 is still being discussed and different values have been
 reported in different studies. Since determining the opti-
 mal cut-off point of the hormone for prediction of ovarian
 response can play an important role in making crucial clini-
 cal decisions for infertile women, this study aimed to pre-
 dict poor and excessive ovarian response using AMH levels
 in IVF candidates.

Materials and methods

In this prospective study, all infertile patients referring to
 the infertility clinic of Mahdieh Hospital since the begin-
 ning of 2011 until the end of 2012 were enrolled in case of
 having these criteria (a) no underlying endocrine disease,
 (b) no use of hormonal drugs during the last 3 months and
 (c) no diagnosis of polycystic ovary syndrome (PCOS)
 based on the Rotterdam criteria and no diagnosis of azoo-
 spermia or severe oligozoospermia. For all infertile patients
 referring to the infertility clinic of Mahdieh Hospital who
 met the inclusion criteria and were candidates for IVF,
 levels of AMH (ELIZA, ng/ml), FSH (RIA, IU/ml) and
 E2 (ECL, pg/ml) were measured at day 2 or 3 of the men-
 strual cycle. None of the patients had received hormonal
 treatment for at least one month. In the next step, patients
 entered a standard long-term treatment cycle with short-
 acting GnRH agonist (Sinafact, Sinagen group) with daily
 dose 50 IU/sQ. It should be noted that Gonadotropin start-
 ing dose was based on patient age and dose adjustment was
 done based on ovarian response. Higher age is accompa-
 nied with need to higher stimulation dose.

GnRH agonist long protocol is a standard approach
 for ovarian stimulation and for reducing bias in this study
 the same protocol was used for all patients. Then, at the
 beginning of the menstrual cycle (days 1–3), patients who
 entered the study underwent basic ultrasound to ensure
 the absence of any underlying pathology. In this study,
 controlled ovarian hyperstimulation started at days 3–4 of
 the cycle and the required dose of human urinary-derived
 HMG (Merional-IBSA-75 IU/ml Amp) was determined and
 administered based on the patient's age and according to
 the protocol adopted by infertility clinic of Mahdieh Hospi-
 tal in Tehran. The control ultrasound was performed every
 3–4 days; the treatment was continued based on the ovarian
 response; and the control ultrasound was performed again
 after 2–3 days. By observation of the dominant follicle (16–
 18 mm), the final intervention was done by injecting HCG
 (10,000 IU, Choriomon, IBSA) and oocytes were harvested
 35–36 h later and passed to the embryologist. Embryo
 transfer was performed 36–48 h later if they were appro-
 priate. Luteal phase support started on the day of oocyte
 retrieval using vaginal progesterone (Cyclogest, 400 mg,

Actover), and continued until week 10 of pregnancy in case of pregnancy. The results of all ultrasounds, tests, ovarian response of each patient and the dose of used medication in each cycle were recorded in the patients' files. Patients were classified into three groups of poor ovarian response (oocytes ≤ 3), normal ovarian response (4–12 oocytes) and excessive ovarian response (oocytes > 12) based on the number of oocytes and embryos.

Anti-Müllerian hormone (AMH) assay

We used the AMH Gen II (catalogue number A79765) (Beckman Coulter, Chaska, MN, USA), which has a sensitivity of 0.57 pmol/l, and reported intra- and inter-assay coefficients of variation of less than 5.4 and 5.6 %, respectively, according to the product insert.

Statistical analysis

Continuous baseline demographic and clinical data are presented as mean \pm standard deviation and grouped data as frequencies and percentages. Chi square test or Fisher's exact test were used to determine the independence of the two categorical variables. One-way ANOVA followed by Tukey's test were employed to investigate the mean difference between different ovarian responses. Pearson correlation coefficient was used to investigate the correlation between the studied variables and outcome and other independent variables. Given that the distribution of AMH concentration was not normal at the beginning, this was done by changing the scale to natural logarithm. In the next and previous steps of fitting a suitable model for calculating the area under curve of the predictor variables, the type of relationship (linear or nonlinear) and its appropriate scale were determined at first using Lowess smoother (locally weighted scatterplot smoothing) and Fracpoly (fractional polynomial regression) and then, the appropriate model for data fitting was used to draw the ROC curve. Comparing the results of Fracpoly with different models in all three multiple regression models of nominal, ordinal and negative binomial showed that in all these models, 0.5 power or AMH natural logarithm scale is the best case to fit them. Considering the continuous nature of AMH concentration in serum and the disadvantages listed for categorization of continuous data, these models were used. Details relating to these models have already been published [18–20]. In order to determine the effect of AMH on the outcomes of ovarian stimulation and different ovarian responses following adjustment of associated variables, the multiple regression models of nominal, ordinal and negative binomial with regarding the over-dispersion criterion were used. All the above models were fitted using backward stepwise selection. The criterion to select the best model was

AIC of these models. Note that in the nominal and ordinal regression models, the response variable was different ovarian responses (no response, poor response, normal response and excessive response) but in the nbreg model, the response variable was the number of oocytes released during the menstrual cycle. Details relating to these models have already been published [21, 22]. R i386 3.0.2 software was used to determine the best cut-off point, the area under the curve, positive and negative predictive values and also the confidence levels for each of the listed values.

Results

This study used data from 188 cases of totally 193 cases of candidates for IVF referring to Mahdih Hospital in Tehran. First, we examined the basic data from the cases studied in Table 1 and then, we discussed the univariate and multivariate analyses and determined the suitable cut-off point for predicting the AMH levels regarding different forms of ovarian response. One-way ANOVA results showed that the mean AMH blood level was different in different groups of ovarian response (no response, poor response, normal response and excessive response) ($F = 8.36, p < 0.001$). The results also revealed that 7.8 % (15) of patients had no ovarian response to treatment, 11.4 % (22) had poor response, 50.8 % (98) had normal response and the rest had excessive ovarian response. Subsequent Tukey's analysis results and the other basic data from the studied cases are summarized in Table 1 based on the type of ovarian response.

According to the table, the use of AM hormone for ovarian stimulation in this study resulted in a positive β -hCG test result or in other words, 30.1 % successful pregnancies. The results of Chi square analysis demonstrated that there was no significant statistical relationship between different ovarian responses and positive pregnancy test results ($p = 0.071$). Pearson correlation analysis results show that there was a strong direct correlation between the concentration of AMH and the number of released oocytes (ovarian response) (Pearson correlation = 0.401 and $p < 0.001$). Furthermore, evaluation of the correlation between the concentration of FSH and ovarian response of the studied subjects indicated that this was an inverse relationship, i.e. the higher the concentration of FSH, the lower the ovarian response (Pearson correlation = -0.245 and $p = 0.001$). These findings can be observed by looking at the numbers given in Table 1.

In order to investigate the effects of different levels of AMH on ovarian response, three different regression models of multi-nominal, ordinal and negative binomial were used with regard to the over-dispersion criterion. Fractional polynomial regression was used to examine the shape of association between the independent variable (in this study, AMH) and the outcome and also the suitable scale

Table 1 Basic information of the studied subjects based on the type of ovarian response

Variable	Category	Ovarian response ^A			
		No response	Poor response (0 < oocyte ≤ 3)	Normal response (4 ≤ oocyte ≤ 12)	Excessive response (oocyte > 12)
Follicle-stimulating hormone	(IU/ml)	9.1 ± 3.8	7.2 ± 5.2	6.9 ± 2.8	5.8 ± 3.01
Anti-Mullerian hormone ^B	(ng/ml)	0.64 ± 0.43 ^a	0.96 ± 0.72 ^a	2.7 ± 2.1 ^a	6.6 ± 4.9 ^b
Estradiol	(pg/ml)	59.1 ± 22.3	77.9 ± 36	155.1 ± 44.1	56.3 ± 33.3
Luteinizing hormone	(IU/ml)	5.95 ± 4.5	4.8 ± 1.4	5.4 ± 3.2	6.5 ± 2.9
Oocyte	Count	–	3.1 ± 1.1	8.6 ± 2.2	18.4 ± 5.1
Embryo	Count	–	2.1 ± 1.02	4.9 ± 2.3	10.1 ± 4.02
β-hCG test	Positive	–	3 (13.6)	33 (33.6)	22 (37.9)
	Negative	193 (100)	19 (86.4)	65 (66.4)	36 (62.1)

^A Showed as mean ± standard deviation and number and percent for continuous and categorical data, respectively

^B Similar lowercase letters indicate the absence of meaningful statistical difference among groups based on Tukey's multiple comparison test

Table 2 Results of the multi-nominal regression models for examining the effects of different levels of AMH on ovarian response in the studied subjects

Variable	Outcomes			
	Normal response	No response	Poor response	Excessive response
	AOR, 95 % CI			
LnAMH	Referent category	0.54 (0.28–1.04)	0.36 ^a (0.19–0.68)	1.71 ^a (1.09–2.7)
E2	Referent category	1 (0.99–1.01)	0.99 (0.98–1.1)	0.98 (0.96–1.1)
LH	Referent category	1.18 (0.93–1.5)	1.05 (0.77–1.43)	1.11(0.95–1.31)
Age	Referent category	1.33 ^a (1.03–1.73)	0.93 (0.8–1.08)	0.92 (0.83–1.02)

^a Significant at 0.05 level

for continuous variables. This model showed that the use of AMH hormone logarithm scale in all three models had the lowest AIC among the investigated models.

Table 2 shows the effects of different blood concentrations of AM hormone on the type of ovarian response in the multi-nominal regression models. All models were fitted based on the backward stepwise method.

Note that in the ordinal model, response variables were defined as no response, poor response, normal response and excessive ovarian response. Regarding the multi-nominal regression, these responses were considered to be nominal. For the negative binomial model, the response variable was considered as the number of oocytes released during the study period.

The results of this model were reported with inserting the normal response as the reference class and use of AIC criterion for fitting the best model. The results showed that with each unit increase in the log of AMH, the odds ratio of having poor response compared to normal response decreases by 64 %. It should also be said that in case of each unit increase in the log of AMH, this value was 71 % greater for excessive response group compared to normal group.

The results of the regression model with proportional odds showed that the odds of individuals to be in each

of the classes of ovarian responses (no response, poor response, normal response and excessive response) different than the previous or next classes would be 2.29 (OR 2.29, 95 % CI 1.64–3.19, *p* value < 0.001).

By placing the number of oocytes released after stimulation by AMH as the response variable, the results of negative binomial regression model indicated that for one unit increase in the log of AMH blood levels, the odds of releasing an oocyte increased 24 % (OR 1.24, 95 % CI 1.14–1.35). Note that in all fitted models, the variable of maternal age was one of the variables affecting the results of the study. For example, the results in Table 2 show that with one unit increase in maternal age, the odds of having a poor response was 1.33 times more than odds of having a normal response. Moreover, with each unit increase in maternal age in nbreg model, the chance of release of each oocyte in the studied subjects decreased 4 % (OR 0.96, 95 % CI 0.93–0.99).

The results also show that the only variable affecting the number of embryos during the treatment was directly related to AMH levels and inversely related to maternal age at the time of infertility treatment. These findings suggest that with each unit increase in the concentration of AMH, the odds of formation of an embryo increased






Fig. 1 The relationship between the natural logarithm of AMH serum levels and poor and excessive ovarian responses using Fracpoly

306 approximately 0.3 % (OR 1.025, 95 % CI 1.01–1.04), also
 307 with each year increase in maternal age, the odds of forma-
 308 tion of an embryo decreased approximately 2 % (OR 0.98,
 309 95 % CI 0.96–0.99).

310 In the next step, the cut-off points for predicting poor, exces-
 311 sive and no ovarian responses compared to normal response
 312 will be discussed. Figure 1 shows the relationship between
 313 AMH blood levels and poor and excessive ovarian responses.

314 Figure 2 indicates the area under the curve and the opti-
 315 mal cut-off point of AMH in association with different
 316 ovarian responses.


317 In all the above cases, normal response was used as
 318 the reference in comparison to excessive, poor and no
 319 **AQ6** responses. Further details are provided in Table 3.

320 The results of this table show that the AMH plasma levels
 321 under 1.2 ng/ml with the area under curve of 0.87 % would
 322 very well predict the no ovarian response. This finding
 323 shows that it can be very well used to distinguish between
 324 normal and no ovarian response with 79 % sensitivity and
 325 93 % specificity. Furthermore, given that in this study
 326 DLR^+ was greater than 1 for all three ovarian responses,
 327 the test is suitable for predicting different ovarian responses.
 328 Note that, given that the excessive ovarian response level
 329 was greater than 3.4 ng/ml and poor ovarian response level
 330 was 1.2, the level of AMH associated with normal ovarian
 331 response should be between 1.2 and 3.4 ng/ml. The other
 332 results in this table can be interpreted similarly.


333 Discussion

334 The results of this study showed that, generally, the use of
 335 standard long-term treatments with GnRH agonist led to


336 positive pregnancy test results in 30 % of treated patients. 336
 337 The optimal cut-off points of AMH for predicting excessive 337
 338 and poor ovarian responses were 3.4 and 1.2 ng/ml, respec- 338
 339 tively, with area under curves of 0.69 and 0.76 %, respec- 339
 340 tively. Furthermore, considering the estimates done for the 340
 341 poor and excessive ovarian responses, the normal ovarian 341
 342 response should be between 1.2 and 3.4 ng/ml. In mature 342
 343 women, AMH is only secreted by the granulosa cells of 343
 344 preantral and small antral follicles and helps the regulation 344
 345 of ovarian function and follicular steroidogenesis. Due to 345
 346 the exclusive production of this hormone in mature women, 346
 347 it can be used as a marker of ovarian activity [23]. In addi- 347
 348 tion, sustained secretion of this hormone (AMH) during 348
 349 the menstrual cycle with no significant changes during and 349
 350 out of the cycle [24, 25] and its plasma levels not being 350
 351 affected by the use of external hormones [17] justifies the 351
 352 use of this indicator for research purposes and determina- 352
 353 tion of secondary causes of oligo-amenorrhoea. In recent 353
 354 years, numerous studies have examined the role of AMH 354
 355 in predicting ovarian response in controlled ovarian hyper- 355
 356 stimulation in IVF candidates. One of the recent studies 356
 357 conducted in this area is by Hamdine et al. [26], and the 357
 358 results of this study indicate that the use of AMH levels 358
 359 alone and as a test has a great accuracy in predicting exces- 359
 360 sive and poor ovarian responses, with the difference that the 360
 361 accuracy was greater for excessive ovarian response com- 361
 362 pared to poor response. In our study, the accuracy for pre- 362
 363 diction of poor ovarian response and no ovarian response 363
 364 was greater than excessive ovarian response. Perhaps the 364
 365 reason for this difference was the distribution of individu- 365
 366 als in different ovarian response groups in the two studies. 366
 367 Several markers have been used in previous studies for the 367
 368 prediction of different ovarian responses or ovarian reserve 368



a ROC curve for predicting the no ovarian response using the AMH level, showing 78% sensitivity at 93% specificity with optimal cut-off point of 1.2 ng/ml.



b ROC curve for predicting the excessive ovarian response using the AMH level, showing 56% sensitivity at 73% specificity with optimal cut-off point of 3.4 ng/mL.



c ROC curve for predicting the poor ovarian response using the AMH level, showing 72% sensitivity at 80% specificity with optimal cut-off point of 1.2ng/ml.

Fig. 2 The AUC of ROC and optimal cut-off points for AMH levels with different ovarian responses

Table 3 Determining the optimal cut-off points for prediction of different ovarian responses using AMH plasma levels in IVF candidates

Outcome	AUC (% 95, CI)	Cut-off point	Youden's index	sensitivity (% 95, CI)	specificity (% 95, CI)	PPV (% 95, CI)	NPV (% 95, CI)	FP (%)	FN (%)	DLR ⁺	DRL ⁻
No response	0.87 (0.80–0.94)	1.2	0.71	0.79 (0.69–0.86)	0.93 (0.68–0.99)	0.987 (0.92–0.992)	0.40 (0.29–0.96)	1	21	11.78 (1.76–78)	0.23 (0.15–0.34)
Poor response	0.76 (0.66–0.86)	1.2	0.53	0.72 (0.63–0.81)	0.81 (0.60–0.93)	0.94 (0.85–0.96)	0.41 (0.31–0.70)	5	30	3.77 (1.69–8.35)	0.34 (0.24–0.48)
Excessive response	0.69 (0.60–0.77)	3.4	0.30	0.57 (0.43–0.69)	0.73 (0.63–0.81)	0.56 (0.44–0.69)	0.74 (0.62–0.82)	26	25	2.14 (1.43–3.19)	0.58 (0.42–0.8)

AUC area under curve, PPV positive predictive value, NPV negative predictive value, FP false positive, FN false negative, DLR diagnostic likelihood ratio

where the antral follicle count (AFC) can be mentioned. The use of this indicator for predicting ovarian reserve prior to IVF is suggested. However, although the ability of this indicator to predict has been reported much better than basal FSH [10], the predictive value of AMH is higher and the unique characteristics of this indicator make the use of this marker for clinical use more logical [26]. In this study, the successful pregnancy rate was approximately 31 % and a negative relationship was observed between age and number of embryos. In the Ficicioglu et al. study, this rate was 39 % and they reported a negative relation between age and AMH levels. This study showed that blood levels of AMH lower than or equal to 1 ng/ml can very well predict the poor ovarian response [27]. With regard to the use of different regression models in this study, it can be stated that the only variables affecting the outcome of the study were AMH serum levels along with the maternal age (in nominal and ordinal multiple regressions of variable responses, different ovarian responses were due to controlled ovarian stimulation where once was considered nominal and once ordinal). In the multi-nominal model it was shown that with each unit increase in the log of AMH, the odds of having a poor response rather than a normal response decreased 64 %. Notable in this model is the role of maternal age, so that with each year increase in maternal age, the chance of having a poor response increased 33 %. Given that categorization of quantitative variables causes residual error in the model (this error can be modified by increasing the number of groups and decreasing the interval between them, but it does not disappear), this study used a model that considered the number of oocytes and embryos as the response variable. This finding is more tangible and understandable for many physicians who do not have much knowledge of the science of statistics. The results showed that for every one unit increase in the log of AMH blood levels, the odds ratio of releasing an oocyte increased 24 %. This model also confirmed the findings of previous models and it was shown that with each unit increase in maternal age, the odds of releasing an oocyte decreased 4 % in the studied individuals. These findings indicate the great importance of considering the maternal age and instruction for treatment in younger ages for mothers who do not have children in the early years of common life. It should also be noted that young women with minimal ovarian reserve who are in fact in the same conditions as older premenopausal women need higher clinical care [4]. Ganidou et al. [28] demonstrated that the use of maternal age, AMH and FSH variables can very well and with high accuracy predict the excessive ovarian response. The study by Vural et al. [29] also showed that maternal age is directly related with poor ovarian response and the odds of a poor response will be greater with the increase in maternal age.



421 Assessment of ovarian reserve before utilizing assisted
 422 reproductive technology is a very important issue, and
 423 knowing that the ovarian response would be poor or exces-
 424 sive, allows the doctor to choose the final method of stimu-
 425 lation to reduce the side effects such as OHSS and to mini-
 426 mize cycle cancellation [30]. The present study suggests that
 427 prediction of poor ovarian response is more accurate than
 428 excessive ovarian response (areas under curve for poor and
 429 excessive response were 0.76 (0.66–0.86) and 0.69 (0.60–
 430 0.77), respectively, with a confidence interval of 95 %).
 431 Regarding the poor ovarian response, the diagnostic ability
 432 of the test to distinguish individuals whose tests were posi-
 433 tive and were really sick was 0.94 %, while this value was
 434 0.56 % for excessive response. In this study, for categoriza-
 435 tion of ovarian responses using the variable of the number of
 436 oocytes released, each of these responses were made using
 437 binary mode and inserted into the next models. Importantly,
 438 the response variable of no ovarian response only included
 439 individuals who did not release any oocytes following the
 440 stimulation but the poor response variable included individ-
 441 uals who released 3 or less oocytes or entirely did not ova-
 442 late. Thus, it can be seen that the optimal cut-off points for
 443 predicting poor ovarian response and no response are 1.2.
 444 However, with considering a greater area under curve for no
 445 response compared to poor response and the lower number
 446 of false positives for no ovarian response, the probability
 447 of an individual with AMH level less than 1.2 being in the
 448 no response class was higher than being in poor response
 449 class. It should be noted that different categories have been
 450 presented for the ovarian reserve in various studies all of
 451 which are similar [29, 31], also the estimated areas under
 452 the ROC curves in this study are better compared to the past
 453 and recent studies and indicates better accuracy of estimates
 454 in this study [26, 32]. It should also be noted that in this
 455 study, the positive diagnostic likelihood ratios, which were
 456 related to former and latter likelihood of developing the dis-
 457 ease, were numbers greater than 1 and along with the other
 458 reported add values in Table 3, encourage the physicians to
 459 use AMH levels for predicting ovarian response in women
 460 with infertility problems. Similarly, negative diagnostic like-
 461 lihood ratios were related to the absence of disease and the
 462 more this value was less than 1, the value of the test for pre-
 463 diction of absence of disease was better. Further information
 464 about the add values and the use of ROC curves have been
 465 previously published [33]. In this study, precise statistical
 466 methods were used for predicting and assessing the rela-
 467 tionship between the studied variables before determining
 468 the optimal cut-off points which resulted in more accurate
 469 estimates and better understanding of the results for use in
 470 clinics by physicians [18]. Finally, it should be noted that
 471 knowing the chances of pregnancy in each cycle allows the
 472 physicians to consult with their patients after assessment of
 473 the patients' condition and before the assisted reproduction

474 intervention and if necessary, use gamete donation or adop-
 475 tion [34].

476 Considering the age of the patient undergoing infer-
 477 tility treatment as a variable affecting ovulation and the
 478 use of AMH levels to predict poor and excessive ovarian
 479 responses as a standard test with high diagnostic value can
 480 be very helpful in determining the strategy for treatment of
 481 these patients. Larger studies with focus on all the variables
 482 affecting the infertility and its underlying causes are highly
 483 recommended.

Acknowledgments The author would like to thank Infertility and
 484 Reproductive Health Research Center of Shahid Beheshti University
 485 of Medical Sciences for their financial support of this study. 486

Conflict of interest The authors have stated explicitly that there are
 487 no conflicts of interest in connection with this article. 488

Ethical standards The proposal of this research has been approved
 489 in the Ethics Committee of Infertility and Reproductive Health
 490 Research Center (IRHRC), Shahid Beheshti University of Medical
 491 Sciences (2014, SBMU, REC 299). 492

Informed consent All the individuals had been informed of the pur-
 493 poses of the study and gave their oral informed consent. 494

495 References

- 496 1. Ubaldi F, Vaiarelli A, D'Anna R, Rienzi L (2014) Management
 497 of poor responders in IVF: is there anything new? *Biomed Res*
 498 *Int* 2014
- 499 2. Jirge PR, Chougule SM, Gavali VG, Bhomkar DA (2014) Impact
 500 of dehydroepiandrosterone on clinical outcome in poor respon-
 501 ders: a pilot study in women undergoing in vitro fertilization,
 502 using bologna criteria. *JHRS* 7:175
- 503 3. Ravhon A, Lavery S, Michael S, Donaldson M, Margara R, Trew
 504 G et al (2000) Dynamic assays of inhibin B and oestradiol fol-
 505 lowing buserelin acetate administration as predictors of ovarian
 506 response in IVF. *Hum Reprod* 15:2297–2301
- 507 4. Fauser B, Diedrich K, Devroey P (2008) Predictors of ovarian
 508 response: progress towards individualized treatment in ovulation
 509 induction and ovarian stimulation. *Hum Reprod Update* 14:1–14
- 510 5. Yassin MM, Sharif FA, Laqqan MM (2013) Anti-mullerian hor-
 511 mone as a predictor of ovarian reserve and ovarian response in
 512 IVF women from Gaza strip. *Iran J Reprod Med* 11:261
- 513 6. Maheshwari A, Fowler P, Bhattacharya S (2006) Assessment of
 514 ovarian reserve—should we perform tests of ovarian reserve rou-
 515 tinely? *Hum Reprod* 21:2729–2735
- 516 7. Lass A, Skull J, McVeigh E, Margara R, Winston R (1997)
 517 Measurement of ovarian volume by transvaginal sonography
 518 before ovulation induction with human menopausal gonadotro-
 519 pin for in vitro fertilization can predict poor response. *Hum*
 520 *Reprod* 12:294–297
- 521 8. Broekmans FJ, Faddy M, te Velde ER (2005) Ovarian reserve
 522 and reproductive age may be determined from measurement
 523 of ovarian volume by transvaginal sonography. *Hum Reprod*
 524 20:1114–1115
- 525 9. Chang M-Y, Chiang C-H, Hsieh T, Soong Y, Hsu K (1998) Use
 526 of the antral follicle count to predict the outcome of assisted
 527 reproductive technologies. *Fertil Steril* 69:505–510

- 528 10. Hendriks DJ, Mol BWJ, Bancsi LF, Te Velde ER, Broekmans
529 FJ (2005) Antral follicle count in the prediction of poor ovar-
530 ian response and pregnancy after in vitro fertilization: a meta-
531 analysis and comparison with basal follicle-stimulating hormone
532 level. *Fertil Steril* 83:291–301
- 533 11. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-
534 Fenning N (2010) A prospective, comparative analysis of anti-
535 Müllerian hormone, inhibin-B, and three-dimensional ultra-
536 sound determinants of ovarian reserve in the prediction of
537 poor response to controlled ovarian stimulation. *Fertil Steril*
538 93:855–864
- 539 12. Van Rooij I, Broekmans F, Te Velde E, Fauser B, Bancsi L, De
540 Jong F et al (2002) Serum anti-Müllerian hormone levels: a
541 novel measure of ovarian reserve. *Hum Reprod* 17:3065–3071
- 542 13. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Ar-
543 tenisio AC et al (2010) Anti-Müllerian hormone (AMH) as a pre-
544 dictive marker in assisted reproductive technology (ART). *Hum*
545 *Reprod Update* 16:113–130
- 546 14. Lin P-Y, Huang F-J, Kung F-T, Chiang H-J, Lin Y-J, Lin Y-C
547 et al (2014) Evaluation of serum anti-mullerian hormone as a
548 biomarker of early ovarian aging in young women undergoing
549 IVF/ICSI cycle. *Int J Clin Exp Pathol* 7:6245
- 550 15. Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS et al (2010)
551 Impact of laparoscopic cystectomy on ovarian reserve: serial
552 changes of serum anti-Müllerian hormone levels. *Fertil Steril*
553 94:343–349
- 554 16. Singh N, Malik E, Banerjee A, Chosdol K, Sreenivas V, Mit-
555 tal S (2013) “Anti-Mullerian hormone: marker for ovarian
556 response in controlled ovarian stimulation for IVF patients”: a
557 first pilot study in the Indian population. *J Obstet Gynecol India*
558 63:268–272
- 559 17. Li HWR, Wong CYG, Yeung WSB, Ho PC, Ng EHY (2011)
560 Serum anti-müllerian hormone level is not altered in women
561 using hormonal contraceptives. *Contraception* 83:582–585
- 562 18. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing con-
563 tinuous predictors in multiple regression: a bad idea. *Stat Med*
564 25:127–141
- 565 19. Jacoby WG (2000) Loess. a nonparametric, graphical tool
566 for depicting relationships between variables. *Electoral Stud*
567 19:577–613
- 568 20. Royston P, Sauerbrei W (2008) Multivariable model-building:
569 a pragmatic approach to regression analysis based on fractional
570 polynomials for modelling continuous variables. Wiley, London
- 571 21. Harrell FE (2001) Regression modeling strategies: with applica-
572 tions to linear models, logistic regression, and survival analysis.
573 Springer, Berlin
- 574 22. Hilbe JM (2011) Negative binomial regression. Cambridge Uni-
575 versity Press, Cambridge
23. Anderson R, Nelson S, Wallace W (2012) Measuring anti-Mül-
576 lerian hormone for the assessment of ovarian reserve: when and
577 for whom is it indicated? *Maturitas* 71:28–33
24. Streuli I, Fraise T, Pillet C, Ibecheole V, Bischof P, De Ziegler
578 D (2008) Serum antimüllerian hormone levels remain stable
579 throughout the menstrual cycle and after oral or vaginal adminis-
580 tration of synthetic sex steroids. *Fertil Steril* 90:395–400
25. La Marca A, Stabile G, Arsenio AC, Volpe A (2006) Serum
581 anti-Mullerian hormone throughout the human menstrual cycle.
582 *Hum Reprod* 21:3103–3107
26. Hamdine O, Eijkemans M, Lentjes E, Torrance H, Macklon
583 N, Fauser B et al (2014) Ovarian response prediction in GnRH
584 antagonist treatment for IVF using anti-Müllerian hormone.
585 *Hum Reprod*, deu266
27. Ficicioglu C, Cenksoy PO, Yildirim G, Kaspar C (2014) Which
586 cut-off value of serum anti-Müllerian hormone level can predict
587 poor ovarian reserve, poor ovarian response to stimulation and in
588 vitro fertilization success? A prospective data analysis. *Gynecol*
589 *Endocrinol* 30:372–376
28. Ganidou MA, Kolibianakis EM, Venetis CA, Gerou S, Makedos
590 GA, Klearchou N et al (2014) Is assessment of anti-mullerian
591 hormone and/or antral follicle count useful in the prediction of
592 ovarian response in expected normal responders treated with a
593 fixed dose of recombinant FSH and GnRH antagonists? A pro-
594 spective observational study. *Gynecol Endocrinol* 30:817–821
29. Vural B, Cakiroglu Y, Vural F, Filiz S (2014) Hormonal and
595 functional biomarkers in ovarian response. *Arch Gynecol Obstet*
596 289:1355–1361
30. Broekmans F, Kwee J, Hendriks D, Mol B, Lambalk C (2006)
597 A systematic review of tests predicting ovarian reserve and IVF
598 outcome. *Hum Reprod Update* 12:685–718
31. Tokura Y, Yoshino O, Ogura-Nose S, Motoyama H, Harada M,
599 Osuga Y et al (2013) The significance of serum anti-Müllerian
600 hormone (AMH) levels in patients over age 40 in first IVF treat-
601 ment. *J Assist Reprod Genet* 30:821–825
32. Verhagen T, Hendriks D, Bancsi L, Mol B, Broekmans F (2008)
602 The accuracy of multivariate models predicting ovarian reserve
603 and pregnancy after in vitro fertilization: a meta-analysis. *Hum*
604 *Reprod Update* 14:95–100
33. Cook NR (2008) Statistical evaluation of prognostic versus diag-
605 nostic models: beyond the ROC curve. *Clin Chem* 54:17–23
34. Elder K, Dale B (2010) In-vitro fertilization. Cambridge Univer-
606 sity Press, Cambridge

Journal:	40618
Article:	297

Author Query Form

Please ensure you fill out your response to the queries raised below and return this form along with your corrections

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ1	Please check and confirm the author names and initials are correct. Also, kindly confirm the details in the metadata are correct.	
AQ2	Please confirm the corresponding author is correctly identified and amend if necessary.	
AQ3	Please update Refs. [1] and [26] with required details.	
AQ4	Please check the edits made to the sentence 'This study used data from...' and amend if necessary.	
AQ5	The labels in figures (1,2) are not readable. Please provide a new figure with legible labels in Vector EPS or tiff / jpeg format with 600 dpi resolution.	
AQ6	Please check the layout of Table 3, and correct if necessary.	
AQ7	Please provide the details regarding "Research involving human participants and/or animals" since it is mandatory for this journal.	